Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A progressive muscle weakness and atrophy of the limbs that irregularly affects certain muscles, while it spares others.
3 FDA-approved treatments are available for adult progressive spinal muscular atrophy, Aran Duchenne type, including RISDIPLAM (EVRYSDI, approved 2020), NUSINERSEN (SPINRAZA, approved 2016), and onasemnogene abeparvovec-xioi (Zolgensma, approved 2019).
Brand Name | Generic Name | Mechanism | Approved |
|---|
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 5:38 PM UTC
Genetic and Rare Diseases Info Center
Common questions about adult progressive spinal muscular atrophy, Aran Duchenne type
EVRYSDI | RISDIPLAM | — | 2020 | Available |
Zolgensma | onasemnogene abeparvovec-xioi | — | 2019 | Available |
SPINRAZA | NUSINERSEN | — | 2016 | Available |
View trials for adult progressive spinal muscular atrophy, Aran Duchenne type